RxDoctor Payments Data

Daisy Boehm

Family · Appleton, WINPI 1194925479

Payments from drug & device makers

$1,315in general payments, 2019–2025

Across 22 payments — averaging $59.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$414
  • E.r. Squibb & Sons, L.L.C.$373
  • Johnson & Johnson$194
  • Lilly USA, LLC$140
  • AstraZeneca$103
  • Merck$45
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,22293%
  • Education$937%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,315 in reported general payments places this provider in the 85th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$42,520
Medicare patients
96
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide38$603,843
KisqaliRibociclib Succinate17$271,670
EliquisApixaban137$119,100
Abiraterone Acetate26$19,190
Ondansetron Hcl60$3,069
Anastrozole147$2,546
Enoxaparin Sodium14$1,779
Hydroxyurea50$1,237
Tamoxifen Citrate52$1,229
Imatinib Mesylate13$1,162
ValacyclovirValacyclovir Hcl13$1,002
Potassium Chloride40$703
Letrozole27$617
Prochlorperazine Maleate40$589
Hydrocortisone17$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$14$603,84338 claims
NovartisKisqali$32$271,67017 claims
Lilly USA, LLCOlanzapine$140$22216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,273 family providers in Wisconsin.

Other family in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →